Jonathan C. Trent, MD, PhD
Dr. Trent is currently the Associate Director for Clinical Research at the Sylvester Comprehensive Cancer Center and the Director of the Bone and Soft-tissue Sarcoma Group.
Dr. Trent’s interests are in the clinical and translational research of sarcomas, direct care of patients with sarcoma, and education about sarcoma. His goal is to develop clinical trials that provide molecular testing of a patient’s tumor to provide molecularly targeted therapy. His work involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, archival tissue, as well as collaborations with disciplines such as the genomics facility, surgical oncology, pathology, radiology and interventional radiology.
Dr. Jonathan C. Trent earned an MD degree and a PhD degree in cancer biology from The University of Texas Health Science Center in San Antonio, where he also completed a residency in internal medicine. He then completed a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center in Houston, where he was also Chief Fellow.
Andrew S. Brohl, MD
Dr. Andrew (Andy) Brohl is a Medical Oncologist and Physician-Scientist at the H. Lee Moffitt Cancer Center. His clinical areas of expertise are in the treatment of patients with sarcoma or melanoma. Dr. Brohl’s research focuses on the use of genomics and other high-throughput technologies for clinically translational applications. Examples of his current projects include genomic analysis of sarcoma subtypes, identification of drug targets from “-omics” datatypes, application of genomics for personalized cancer therapy, and development of noninvasive molecular profiling technology. He additionally is a member of the analysis team for the National Institutes of Health’s “The Cancer Genome Atlas” sarcoma project. Dr. Brohl’s research has been published in peer-reviewed journals including Lancet Oncology, Cancer Discovery, PLOS Genetics, and Clinical Cancer Research.
Dr. Brohl earned an MD degree from the University of Miami, Miller School of Medicine. He completed an internal medicine residency at Georgetown University and a hematology and medical oncology fellowship at the National Cancer Institute.
George D. Demetri, MD
At Dana-Farber Cancer Institute and Harvard Medical School, Dr. George Demetri leads a large multidisciplinary team focused on the specialty cancer care and science of sarcomas that has consistently been at the cutting edge of developing personalized cancer therapeutics for sarcomas as a model for all cancers.
Dr. Demetri has long been a leader in translational research aimed at developing the most rational practical applications of new discoveries to understand and treat sarcomas. He was a pioneer in the development of one of the first examples of targeted cancer therapies focused on a molecularly defined subset of sarcoma: gastrointestinal stromal tumor. He has served as a member of the institutional review board for the Dana-Farber Cancer Institute since 1994. Outside of the laboratory, Dr. Demetri has been instrumental in raising awareness of issues relating to sarcoma, serving as a chairperson of the medical advisory board of the Sarcoma Foundation of America, and a board member of the Hope Funds for Cancer Research.
Dr. Demetri earned an MD degree from Stanford University School of Medicine, after which he completed an internal medicine residency and chief residency at the University of Washington Hospitals in Seattle. He completed a fellowship in medical oncology at the Dana-Farber Cancer Institute and Harvard Medical School.
Kristen N. Ganjoo, MD
Dr. Kristen Ganjoo is an Associate Professor of Medicine at Stanford University Medical Center, and a sarcoma specialist in the sarcoma program at the Stanford Cancer Center.
Dr. Ganjoo’s work focuses on sarcoma, including soft tissue, gastrointestinal stromal, and Ewing malignancies. Her clinical research focus is on new and novel therapies for sarcomas. Dr. Ganjoo has been involved in the initial and ongoing development of targeted agents for sarcoma and was an integral investigator in the clinical development of several drugs that are now approved by the US Food and Drug Administration. Dr. Ganjoo is a member of the Sarcoma Alliance for Research through Collaboration Clinical Research Committee. Dr. Ganjoo’s research has been published in peer-reviewed journals, including the JAMA, Journal of Surgical Oncology, Journal of Clinical Oncology, and Cancer.
Dr. Ganjoo earned an MD degree from the University of South Alabama and completed a residency in internal medicine and a fellowship in hematology/oncology at Indiana University Medical Center.
Scott H. Okuno, MD
Dr. Scott H. Okuno is a Professor of Oncology and the Sarcoma Tumor Chairperson in the Division of Medical Oncology at Mayo Clinic in Rochester, Minnesota.
Dr. Okuno’s work focuses on clinical trials for bone and soft-tissue sarcoma. He is the Medical Officer for the Sarcoma Alliance for Research through Collaboration and collaborates with sarcoma researchers in the Midwest Sarcoma Trials Partnership as well as the Sarcoma Working Group of NRG Oncology.
Dr. Okuno earned an MD degree from the University of Illinois at Chicago and completed a residency in internal medicine and a fellowship in hematology and oncology at Mayo Clinic Graduate School of Medicine in Rochester, Minnesota.
Raphael E. Pollock, MD, PhD, FACS
Dr. Raphael E. Pollock is Professor and Director of the Division of Surgical Oncology at The Ohio State University Wexner Medical Center. He also serves as Surgeon in Chief for the James Comprehensive Cancer Center and The Ohio State University Health System.
Dr. Pollock’s work focuses on soft-tissue sarcoma. His laboratory research activities are examining multiple facets of the molecular pathways of soft-tissue sarcoma inception, progression, and therapy. His laboratory research activities have been continuously funded by the National Institutes of Health.
Dr. Pollock earned an MD degree from the St. Louis School of Medicine in Missouri and a PhD degree from the University of Texas Graduate School of Biological Sciences in Houston. He completed a residency in general surgery at the University of Chicago and Rush Presbyterian St. Luke’s Medical Center followed by a fellowship in surgical oncology at the University of Texas MD Anderson Cancer Center.
Richard F. Riedel, MD
Dr. Richard F. Riedel is an Associate Professor of Medicine and Member of the Duke Cancer Institute. He additionally serves as the Associate Director for Clinical and Translational Research for the Duke Sarcoma Program.
Dr. Riedel is a nationally recognized expert in the treatment of bone and soft-tissue sarcomas. He is a member of the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology sarcoma panel, a past member and chairperson of the American Society of Clinical Oncology sarcoma education committee, and a member of the Sarcoma Alliance for Research through Collaboration Clinical Research Committee. He additionally serves on the medical advisory board for the Sarcoma Foundation of America.
Dr. Riedel earned an MD degree from Jefferson Medical College and completed a residency in internal medicine, chief residency, and a fellowship in hematology/oncology at Duke University Medical Center.
Gary K. Schwartz, MD
Dr. Gary K. Schwartz is a Professor of Medicine at the Columbia University College of Physicians and Surgeons, Director of the Division of Hematology and Medical Oncology, and Associate Director of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center.
Dr. Schwartz’ work focuses on melanoma, sarcoma, and new drug development. His primary research has been in the identification of new targeted agents for cancer therapy, especially in the treatment of melanoma and sarcoma. His research has been supported by the National Cancer Institute, the Lustgarten Foundation for Pancreatic Cancer, the Department of Defense for Breast Cancer Research, the Byrne Foundation, and the US Food and Drug Administration. Results of his research have been published in peer-reviewed journals, including the Journal of Clinical Oncology, Lancet, and JAMA. Dr. Schwartz is Associate Editor of the Journal of Clinical Oncology, Vice Chairperson of the the American Society of Clinical Oncology’s Targeted Agent and Profiling Utilization Registry Study Molecular Tumor Board, member of the Cancer Education Committee of the American Society of Clinical Oncology (Track Leader), and serves on National Cancer Institute study sections including the NExT Committee. In addition, he is Co-Chairperson of the Experimental Therapeutics Committee of the Alliance for Clinical Trials Oncology.
Dr. Schwartz earned an MD degree from Albany Medical College in New York and completed a residency in internal medicine at North Shore University Hospital in Manhassett, New York; and a fellowship in hematology/oncology at Icaahn School of Medicine at Mount Sinai, New York.
Brian A. Van Tine, MD, PhD
Dr. Brian A. Van Tine is an Assistant Professor of Medicine at Washington University in Saint Louis School of Medicine in the Department of Internal Medicine, Division of Medical Oncology, and Leader of the Sarcoma Program at Washington University in St. Louis.
Dr. Van Tine’s work focuses on adult and pediatric sarcomas. His primary research has been in both the basic science of sarcoma as well as clinical translation. His laboratory has a special focus on sarcoma biomarkers and cancer metabolism. Dr. Van Tine has been involved in the initial and ongoing development of new therapeutic drugs for metastatic sarcoma. His research has been published in peer-reviewed journals, including the Journal of Clinical Oncology, Oncotarget, Cell Research, and Lancet Oncology, the Journal of Clinical Oncology, and Nature.
Dr. Van Tine earned MD and PhD degrees from The University of Alabama at Birmingham and completed a residency in internal medicine and a fellowship in oncology at Washington University in Saint Louis/Barnes Jewish Hospital.
Margaret von Mehren, MD
Dr. von Mehren is a Professor of Medical Oncology and Associate Director of Clinical Research at the Fox Chase Cancer Center. She also serves as the Director of the Sarcoma Oncology Program.
Dr. von Mehren is an international expert in gastrointestinal stromal tumors and soft-tissue sarcoma. Her career has focused on developmental therapeutics for these rare tumors and she has lead and participated in multiple clinical trials ranging from phase 1 to phase 3. She has written or co-written more than 100 peer-reviewed articles and is the Chairperson of the National Comprehensive Cancer Center Network® Clinical Practice Guidelines in Oncology on soft-tissue sarcomas panel.
Dr. von Mehren earned an MD degree from Albany Medical College in New York. She completed a residency in internal medicine at New York University Medical Center and a fellowship in medical oncology at Fox Chase Cancer Center.